BTK (T474I)
Sign in to save this workspaceBTK · Variant type: point · HGVS: p.T474I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Entrectinib | 100.0% | 0.0% | 93.69 |
| 2 | Canertinib | 100.0% | 0.0% | 96.49 |
| 3 | Gilteritinib | 99.3% | 0.8% | 88.97 |
| 4 | Zanubrutinib | 98.9% | 1.1% | 98.24 |
| 5 | Repotrectinib | 95.2% | 4.8% | 84.21 |
| 6 | Vandetanib | 89.6% | 10.4% | 95.74 |
| 7 | Selpercatinib | 88.0% | 12.0% | 96.72 |
| 8 | Lazertinib | 84.1% | 15.9% | 97.47 |
| 9 | Pacritinib | 82.6% | 17.4% | 88.64 |
| 10 | Pralsetinib | 82.5% | 17.5% | 93.43 |
| 11 | Neratinib | 81.0% | 19.0% | 93.18 |
| 12 | Sunitinib | 78.1% | 21.9% | 91.73 |
| 13 | Alpelisib | 74.3% | 25.7% | 97.22 |
| 14 | Acalabrutinib | 63.4% | 36.6% | 99.50 |
| 15 | Futibatinib | 60.9% | 39.1% | 98.48 |
| 16 | Pirtobrutinib | 58.4% | 41.6% | 99.49 |
| 17 | Mobocertinib | 49.9% | 50.1% | 97.22 |
| 18 | Defactinib | 49.0% | 51.0% | 92.68 |
| 19 | Tenalisib | 38.6% | 61.4% | 97.98 |
| 20 | Fedratinib | 35.1% | 64.9% | 96.21 |
| 21 | Tivozanib | 33.7% | 66.3% | 92.42 |
| 22 | Erlotinib | 23.1% | 76.9% | 99.75 |
| 23 | Remibrutinib | 17.9% | 82.1% | 99.50 |
| 24 | Paxalisib | 13.3% | 86.7% | 99.75 |
| 25 | Rabusertib | 10.5% | 89.5% | 98.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Entrectinib | 100.0% | 95.1% | +4.9% |
| Canertinib | 100.0% | 99.3% | +0.7% |
| Gilteritinib | 99.3% | 87.6% | +11.7% |
| Zanubrutinib | 98.9% | 97.4% | +1.5% |
| Repotrectinib | 95.2% | 93.7% | +1.5% |
| Vandetanib | 89.6% | 83.8% | +5.8% |
| Selpercatinib | 88.0% | — | — |
| Lazertinib | 84.1% | — | — |
| Pacritinib | 82.6% | 80.3% | +2.3% |
| Pralsetinib | 82.5% | — | — |
| Neratinib | 81.0% | 93.9% | -12.9% |
| Sunitinib | 78.1% | — | — |
| Alpelisib | 74.3% | — | — |
| Acalabrutinib | 63.4% | 95.9% | -32.4% |
| Futibatinib | 60.9% | — | — |
| Pirtobrutinib | 58.4% | 97.7% | -39.3% |
| Mobocertinib | 49.9% | 97.4% | -47.5% |
| Defactinib | 49.0% | — | — |
| Tenalisib | 38.6% | — | — |
| Fedratinib | 35.1% | — | — |
| Tivozanib | 33.7% | — | — |
| Erlotinib | 23.1% | — | — |
| Remibrutinib | 17.9% | 97.7% | -79.8% |
| Paxalisib | 13.3% | — | — |
| Rabusertib | 10.5% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_large_intestine | Large Intestine | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 22.7ms